Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Long-Term Investments (2021 - 2022)

Senti Biosciences has reported Long-Term Investments over the past 2 years, most recently at $230.0 million for Q1 2022.

  • Quarterly results put Long-Term Investments at $230.0 million for Q1 2022, changed N/A from a year ago — trailing twelve months through Mar 2022 was $230.0 million (changed N/A YoY), and the annual figure for FY2021 was $230.0 million, changed.
  • Long-Term Investments for Q1 2022 was $230.0 million at Senti Biosciences, roughly flat from $230.0 million in the prior quarter.
  • Over the last five years, Long-Term Investments for SNTI hit a ceiling of $230.0 million in Q1 2022 and a floor of $230.0 million in Q2 2021.